{
  "docId": "019de070-fbaf-759b-8cbd-9f18172b1352",
  "docSlug": "7d8ead18d80cb869cda17e33a74aeb0b",
  "documentTitle": "BioNTech | Results Presentation Deck | 30 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 30,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a schematic of the mRNA construct and clinical data plots (flow cytometry and longitudinal response).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fbaf-759b-8cbd-9f18172b1352/16",
  "deckHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352",
  "deckJsonHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352.json",
  "deckAnchorHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.46,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Change from baseline in target lesion (%) over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28e4fe36-2733-482b-8af9-a2ad897c064f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.46,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Flow cytometry plot showing 10.1% response",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b53a1cfa-cda5-4dcd-855f-700a9ca9e889",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "image",
      "text": "mRNA construct schematic",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bda2023-ba3d-4006-81eb-b8f76d919d2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Fixed combination of non-nucleoside modified mRNA; Encodes 4 tumor-associated antigens (TAA) covering ~95% of melanoma patients; Intravenous formulation targets antigen presenting cells bodywide to stimulate antigen-specific T cell responses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b34c810-f027-4a09-b17d-ebc05fc38f78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "list",
      "text": "Tolerable safety as monotherapy and in combination with CPI; Durable Objective Responses in CPI-experienced patients; ORR 35% for combination therapy; High-magnitude and persistent CD4+ and CD8+ T cell responses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fc5550b-9d55-4bf4-adef-4216a0ee714a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "other",
      "text": "Nature publication citation box",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f62f525-7d19-4ab3-85a8-0ad9e517e8cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT111: FixVac Melanoma Compelling Preliminary Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6d36450-861c-44ec-8338-490660c17ace",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 9,
      "beatId": "ee869738-53c1-47a5-8d6b-a801587c68e3",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck showcases progress on COVID-19 vaccine strategy and oncology innovation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "acfebc91-ffe5-4ab0-8668-9619a540ee49",
      "evidence": "The deck explains the company's approach to immunotherapy and its potential",
      "position": 0,
      "objective": "Why BioNTech's immunotherapy approach is effective",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}